Longitudinal Quality-of-Life Analysis of RTOG 94-05 (Int 0123):A Phase III Trial of Definitive Chemoradiotherapy for Esophageal Cancer

摘要: Background Longitudinal quality of life (QoL) was compared for patients with esophageal cancer receiving definitive chemoradiotherapy (CRT) conventional-dose (CD) vs. high-dose (HD) radiotherapy as used in the RTOG phase III 94-05 trial (Intergroup 0123). Methods Between June 12, 1995, and July 1, 1999, 236 cT1-4NxM0 were randomized to CD CRT (50.4 Gy concurrent 5-fluorouracil cisplatin) HD (64.8 same chemotherapy). QoL assessed using Functional Assessment Cancer Therapy, Head & Neck (version 2) at baseline, after CRT, 8 months from start 1 year. Results Of 218 eligible patients, 166 participated pretreatment assessments (82 HD, 84 CD). Patients ≥10% weight loss Karnofsky Performance Status 60-80 less likely participate (P = .02 P .002, respectively). Pretreatment characteristics participating similar both arms. At completion, 96 completed (46 50 CD) assessment. Total mean significantly lower arm .02) remained 12 but these values did not reach statistical significance. Change baseline each three subsequent assessment time points differ between two treatment Conclusions For treated cancer, radiation dose escalation 64.8 does improve QoL. These results provide additional evidence that 50.4 should remain standard care.